Scythian (TSXV: $SCYB.V) Retains Investor Relations Services
TORONTO - October 19, 2017 (Investorideas.com Newswire) Scythian Biosciences Corp. (the "Company" or "Scythian") (TSXV: SCYB) (9SB.F) (OTC Pink:SCCYF) announces that is has entered into an agreement with Star Finance GmbH ("Star Finance") under which Star Finance will perform investor relations services for the Company as well as providing business development and management advisory services. The term of the agreement is for an initial six month period ending February 14, 2018. Star will receive a fee of $3,000 per month.
"As we have now received a listing on the Frankfurt exchange, we are pleased to engage with Star Finance to help introduce Scythian to the European marketplace," stated Jonathan Gilbert, CEO.
Star Finance has advised that it does not hold directly, or indirectly, any securities of the Company, nor any right to acquire an interest in the Company.
About Star Finance
Star Finance is a Swiss company owned by Star IR GmbH, which is in turn owned by Michael Adams, with offices in Steinhausen, Switzerland and Cologne, Germany, that specializes in maximizing investor awareness for small and microcap companies within the German-speaking financial community through the implementation of proactive communication strategies. Michael Adams has over 15 years of experience working in the financial communications industry and has established a loyal and extensive network in the German-speaking investment community as well as long standing personal contacts with investment related media channels.
About Scythian Biosciences Corp.
Scythian is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.
Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities
Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.
Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.
For further information, please contact:
Scythian Biosciences Corp.
Phone: (212) 729-9208
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or operating results (as applicable). Although the Company believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including the risk factors discussed in the Filing Statement and the registration statement which are incorporated herein by reference and are available through SEDAR at www.sedar.com and on the SEC EDGAR filing service at www.sec.gov. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Scythian Biosciences Corp. (TSX.V: SCYB)
is a Featured biotech and marijuana company on Investorideas.com
Visit Profile page: http://www.investorideas.com/CO/SCYB/Get News Alerts on Scythian Biosciences Corp.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.